Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
41
BHC Quote, Financials, Valuation and Earnings
Last price:
$6.08
Seasonality move
:
-3.4%
Day range:
$5.97 - $6.20
52-week range:
$4.25 - $8.69
Dividend yield:
0%
P/E ratio:
6.27x
P/S ratio:
0.23x
P/B ratio:
--
Volume:
2.5M
Avg. volume:
2.1M
1-year change:
-4.55%
Market cap:
$2.3B
Revenue:
$9.6B
EPS (TTM):
$0.97
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BHC
Bausch Health Cos., Inc.
|
$2.7B | $1.26 | 7.28% | 399.47% | $7.43 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 20.79% | 10.43% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$100K | -- | -42.53% | -- | $4.50 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.12 | -- | -68.5% | $10.30 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.20 | -100% | -36.92% | $55.82 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BHC
Bausch Health Cos., Inc.
|
$6.08 | $7.43 | $2.3B | 6.27x | $0.00 | 0% | 0.23x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$14.51 | $16.67 | $1.9B | 25.86x | $0.00 | 0% | 7.70x |
|
EDSA
Edesa Biotech, Inc.
|
$1.07 | $11.00 | $7.5M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.64 | $4.50 | $15.9M | -- | $0.00 | 0% | 23.44x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.85 | $10.30 | $91.8M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$42.76 | $55.82 | $3.3B | -- | $0.00 | 0% | 449.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BHC
Bausch Health Cos., Inc.
|
102.76% | 1.964 | 635.6% | 0.78x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | 0.004 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -1.338 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.03% | -0.383 | 0.43% | 3.04x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.996 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | -0.106 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BHC
Bausch Health Cos., Inc.
|
$1.7B | $717M | 1.5% | -- | 26.74% | $316M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
-$24.2K | -$1.6M | -186.06% | -189.86% | -2155.4% | -$989.2K |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
Bausch Health Cos., Inc. vs. Competitors
-
Which has Higher Returns BHC or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of 42.95%. Bausch Health Cos., Inc.'s return on equity of -- beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital BHCBausch Health Cos., Inc.62.59% $0.48 $21.4B AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About BHC or AUPH?
Bausch Health Cos., Inc. has a consensus price target of $7.43, signalling upside risk potential of 22.18%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 14.86%. Given that Bausch Health Cos., Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Bausch Health Cos., Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHCBausch Health Cos., Inc.0 7 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is BHC or AUPH More Risky?
Bausch Health Cos., Inc. has a beta of 0.416, which suggesting that the stock is 58.437% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.504, suggesting its more volatile than the S&P 500 by 50.415%.
-
Which is a Better Dividend Stock BHC or AUPH?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC or AUPH?
Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Bausch Health Cos., Inc.'s net income of $181M is higher than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 6.27x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 25.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.23x versus 7.70x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHCBausch Health Cos., Inc.0.23x 6.27x $2.7B $181M AUPHAurinia Pharmaceuticals, Inc.7.70x 25.86x $73.5M $31.6M
-
Which has Higher Returns BHC or EDSA?
Edesa Biotech, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of --. Bausch Health Cos., Inc.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital BHCBausch Health Cos., Inc.62.59% $0.48 $21.4B EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About BHC or EDSA?
Bausch Health Cos., Inc. has a consensus price target of $7.43, signalling upside risk potential of 22.18%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 928.04%. Given that Edesa Biotech, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Edesa Biotech, Inc. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHCBausch Health Cos., Inc.0 7 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is BHC or EDSA More Risky?
Bausch Health Cos., Inc. has a beta of 0.416, which suggesting that the stock is 58.437% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.208, suggesting its less volatile than the S&P 500 by 79.169%.
-
Which is a Better Dividend Stock BHC or EDSA?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC or EDSA?
Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $181M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 6.27x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.23x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHCBausch Health Cos., Inc.0.23x 6.27x $2.7B $181M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns BHC or LEXX?
Lexaria Bioscience Corp. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of -2178.51%. Bausch Health Cos., Inc.'s return on equity of -- beat Lexaria Bioscience Corp.'s return on equity of -189.86%.
Company Gross Margin Earnings Per Share Invested Capital BHCBausch Health Cos., Inc.62.59% $0.48 $21.4B LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M -
What do Analysts Say About BHC or LEXX?
Bausch Health Cos., Inc. has a consensus price target of $7.43, signalling upside risk potential of 22.18%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 605.77%. Given that Lexaria Bioscience Corp. has higher upside potential than Bausch Health Cos., Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHCBausch Health Cos., Inc.0 7 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is BHC or LEXX More Risky?
Bausch Health Cos., Inc. has a beta of 0.416, which suggesting that the stock is 58.437% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.753%.
-
Which is a Better Dividend Stock BHC or LEXX?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC or LEXX?
Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Lexaria Bioscience Corp. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $181M is higher than Lexaria Bioscience Corp.'s net income of -$1.6M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 6.27x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.23x versus 23.44x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHCBausch Health Cos., Inc.0.23x 6.27x $2.7B $181M LEXXLexaria Bioscience Corp.23.44x -- -- -$1.6M
-
Which has Higher Returns BHC or ONCY?
Oncolytics Biotech, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of --. Bausch Health Cos., Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital BHCBausch Health Cos., Inc.62.59% $0.48 $21.4B ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About BHC or ONCY?
Bausch Health Cos., Inc. has a consensus price target of $7.43, signalling upside risk potential of 22.18%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $10.30 which suggests that it could grow by 1107.32%. Given that Oncolytics Biotech, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHCBausch Health Cos., Inc.0 7 0 ONCYOncolytics Biotech, Inc.4 1 0 -
Is BHC or ONCY More Risky?
Bausch Health Cos., Inc. has a beta of 0.416, which suggesting that the stock is 58.437% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.202%.
-
Which is a Better Dividend Stock BHC or ONCY?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC or ONCY?
Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $181M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 6.27x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.23x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHCBausch Health Cos., Inc.0.23x 6.27x $2.7B $181M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns BHC or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of -867.29%. Bausch Health Cos., Inc.'s return on equity of -- beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital BHCBausch Health Cos., Inc.62.59% $0.48 $21.4B XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About BHC or XENE?
Bausch Health Cos., Inc. has a consensus price target of $7.43, signalling upside risk potential of 22.18%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.82 which suggests that it could grow by 30.55%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHCBausch Health Cos., Inc.0 7 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is BHC or XENE More Risky?
Bausch Health Cos., Inc. has a beta of 0.416, which suggesting that the stock is 58.437% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.957, suggesting its less volatile than the S&P 500 by 4.276%.
-
Which is a Better Dividend Stock BHC or XENE?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC or XENE?
Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $181M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 6.27x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.23x versus 449.37x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHCBausch Health Cos., Inc.0.23x 6.27x $2.7B $181M XENEXenon Pharmaceuticals, Inc.449.37x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is up 29.7% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is up 26.39% over the past day.
Buy
73
AEHR alert for Feb 12
Aehr Test Systems [AEHR] is up 26.09% over the past day.
